Trial Profile
A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Siltuximab (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Centocor; Janssen Biotech
- 05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database. (2011-09-08)
- 02 Feb 2020 This trial has been discontinued in Netherlands as per EudraCT Database
- 11 Aug 2012 Additional trial location (Germany) added as reported by European Clinical Trials Database.